Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Gulick

Showing results (81-90 of 155) with videos related to

Pageof 16
Sort By:
Journal of Virology|May 23, 2008
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subjectAthe M N Tsibris, Manish Sagar, Roy M Gulick, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2014
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDSAdriana Weinberg, Ronald Bosch, Kara Bennett, et al.
Annals of Internal Medicine|July 1, 2014
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial dataKatie R Mollan, Marlene Smurzynski, Joseph J Eron, et al.
Pharmacogenetics and Genomics|December 3, 2014
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocolsDavid S Lehmann, Heather J Ribaudo, Eric S Daar, et al.
Plos Genetics|April 26, 2021
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adultsBinglan Li, Yogasudha Veturi, Anurag Verma, et al.
AIDS and Behavior|July 31, 2024
Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP TrialStanley E Cooper, Shuaiqi Zhang, Daniel Haines, et al.
AIDS (London, England)|October 23, 2003
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudineRoy M Gulick, Anne Meibohm, Diane Havlir, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonistsTimothy J Henrich, Nicolas R P Lewine, Sun-Hee Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
Pageof 16

Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
Journal of Virology|May 23, 2008
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subjectAthe M N Tsibris, Manish Sagar, Roy M Gulick, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2014
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDSAdriana Weinberg, Ronald Bosch, Kara Bennett, et al.
Annals of Internal Medicine|July 1, 2014
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial dataKatie R Mollan, Marlene Smurzynski, Joseph J Eron, et al.
Pharmacogenetics and Genomics|December 3, 2014
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocolsDavid S Lehmann, Heather J Ribaudo, Eric S Daar, et al.
Plos Genetics|April 26, 2021
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adultsBinglan Li, Yogasudha Veturi, Anurag Verma, et al.
AIDS and Behavior|July 31, 2024
Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP TrialStanley E Cooper, Shuaiqi Zhang, Daniel Haines, et al.
AIDS (London, England)|October 23, 2003
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudineRoy M Gulick, Anne Meibohm, Diane Havlir, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonistsTimothy J Henrich, Nicolas R P Lewine, Sun-Hee Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
Pageof 16